| Literature DB >> 30458848 |
Rongjiong Zheng1, Zhennan Du1, Mingming Wang1, Yushan Mao2, Wenjie Mao3.
Abstract
BACKGROUND: Triglyceride and glucose (TyG) index and nonalcoholic fatty liver disease (NAFLD) both bave been related to insulin resistance (IR). The study aimed to investigate the longitudinal relationship between TyG index and NAFLD and to evaluate the ability of TyG, through comparing with the predictive value of other indexes, to identify individuals at risk for NAFLD.Entities:
Keywords: Epidemiology; Insulin resistance; Nonalcoholic fatty liver disease; The triglyceride and glucose index
Mesh:
Substances:
Year: 2018 PMID: 30458848 PMCID: PMC6247753 DOI: 10.1186/s12944-018-0913-3
Source DB: PubMed Journal: Lipids Health Dis ISSN: 1476-511X Impact factor: 3.876
Baseline characteristics of the subjects according to TyG quartiles
| Variables | TyG quartiles | ||||
|---|---|---|---|---|---|
| Quartile 1 ( | Quartile 2 ( | Quartile 3 ( | Quartile 4 ( |
| |
| Gender (male/%) | 751/66.6 | 754/65.8 | 748/66.0 | 743/65.6 | 0.96 |
| Age (years) | 38.0(32.0–45.0) | 40.0(34.0–49.0) | 43.0 (35.0–53.0) | 47.0 (38.0–56.0) | < 0.001 |
| BMI (kg/m2) | 21.0 (19.6–23.0) | 21.7 (20.0–23.7) | 22.7 (21.0–24.4) | 23.4 (21.8–25.0) | < 0.001 |
| SBP (mmHg) | 114.0 (106.0–123.0) | 116.0 (108.0–126.0) | 120.0 (111.0–129.0) | 123.0 (114.0–132.0) | < 0.001 |
| DBP (mmHg) | 72.0 (67.0–78.0) | 74.0 (68.0–80.0) | 76.0 (70.0–83.0) | 78.0 (73.0–84.0) | < 0.001 |
| WC (cm) | 73.0 (68.0–79.0) | 75.0 (70.0–81.0) | 78.0 (72.0–83.0) | 80.0 (75.0–85.0) | < 0.001 |
| TyG | 7.79 (7.63–7.94) | 8.17 (8.07–8.28) | 8.49 (8.38–8.61) | 8.97 (8.80–9.20) | < 0.001 |
| BUN (μmol/l) | 4.97 (4.24–5.79) | 4.95 (4.25–5.77) | 5.02 (4.18–5.87) | 4.96 (4.17–5.76) | 0.683 |
| Cr (μmol/l) | 72.0 (60.0–81.0) | 73.0 (61.0–81.0) | 73.0 (61.0–82.0) | 71.0 (60.0–81.0) | 0.353 |
| FPG (mmol/l) | 4.25 (4.00–4.52) | 4.40 (4.12–4.67) | 4.49 (4.21–4.84) | 4.68 (4.33–5.11) | < 0.001 |
| UA (μmol/l) | 303.0 (247.0–350.0) | 305.0 (251.8–357.3) | 324.0 (262.0–384.0) | 336.0 (276.0–390.0) | < 0.001 |
| AST (U/l) | 18.0 (16.0–22.0) | 19.0 (16.0–22.0) | 20.0 (17.0–23.0) | 20.0 (17.0–24.0) | < 0.001 |
| ALT (U/l) | 18.0 (14.0–25.0) | 20.0 (15.0–27.0) | 22.0 (16.0–32.0) | 24.0 (18.0–35.0) | < 0.001 |
| y-GGT (U/l) | 14.0 (11.0–19.0) | 16.0 (11.0–21.0) | 18.0 (13.0–27.0) | 21.0 (15.0–35.0) | < 0.001 |
| TC (mmol/l) | 4.28 (3.78–4.82) | 4.55 (4.04–5.09) | 4.74 (4.20–5.33) | 5.12 (4.54–5.77) | < 0.001 |
| TG (mmol/l) | 0.71 (0.60–0.82) | 1.01 (0.88–1.14) | 1.35 (1.16–1.54) | 2.09 (1.71–2.65) | < 0.001 |
| HDL-C (mmol/l) | 1.38 (1.12–1.70) | 1.31 (1.09–1.60) | 1.24 (1.05–1.53) | 1.24 (1.071.48) | < 0.001 |
| LDL-C (mmol/l) | 2.27 (1.90–2.68) | 2.56 (2.06–3.03) | 2.67 (2.24–3.20) | 2.90 (2.36–3.44) | < 0.001 |
| Apo-A1(g/l) | 1.33 (1.17–1.50) | 1.33 (1.16–1.50) | 1.31 (1.13–1.50) | 1.30 (1.12–1.53) | 0.228 |
| Apo-B(g/l) | 0.77 (0.64–0.90) | 0.85 (0.72–0.98) | 0.93 (0.80–1.08) | 1.04 (0.88–1.22) | < 0.001 |
| eGFR (ml/(min·1.73 m2)) | 112.3 (99.9–127.7) | 109.7 (99.9–123.4) | 108.5 (96.6–123.0) | 107.0 (96.0–123.4) | < 0.001 |
Baseline characteristics of the subjects according to follow-up outcomes
| Variables | Subjects developed NAFLD ( | Subjects did not develop NAFLD ( |
|
|---|---|---|---|
| Gender (male/female, | 1109/281 | 1887/1262 | < 0.001 |
| Age (years) | 41.0(34.0–51.0) | 41.0 (35.0–51.0) | 0.226 |
| BMI (kg/m2) | 23.9 (22.2–25.3) | 21.5 (19.9–23.3) | < 0.001 |
| SBP (mmHg) | 122.0 (114.0–131.0) | 116.0 (107.0–126.0) | < 0.001 |
| DBP (mmHg) | 78.0 (72.0–84.0) | 74.0 (68.0–80.0) | < 0.001 |
| WC (cm) | 82.0 (77.0–87.0) | 74.0 (69.0–80.0) | < 0.001 |
| TyG | 8.58 (8.25–8.91) | 8.21 (7.91–8.54) | < 0.001 |
| BUN (μmol/l) | 5.03 (4.23–5.86) | 4.95 (4.19–5.75) | 0.029 |
| Cr (μmol/l) | 75.0 (65.0–83.0) | 70.0 (59.0–80.0) | < 0.001 |
| FPG (mmol/l) | 4.47 (4.15–4.82) | 4.43 (4.14–4.77) | 0.114 |
| UA (μmol/l) | 347.0 (294.0–401.0) | 301.0 (245.0–356.0) | < 0.001 |
| AST (U/l) | 20.0 (17.0–24.0) | 19.0 (16.0–22.0) | < 0.001 |
| ALT (U/l) | 26.0 (19.0–37.0) | 19.0 (14.0–26.0) | < 0.001 |
| y-GGT (U/l) | 21.0 (15.0–33.0) | 15.0 (11.0–22.0) | < 0.001 |
| TC (mmol/l) | 4.77 (4.17–5.41) | 4.61 (4.03–5.24) | < 0.001 |
| TG (mmol/l) | 1.48 (1.10–2.04) | 1.03 (0.79–1.39) | < 0.001 |
| HDL-C (mmol/l) | 1.20 (1.05–1.43) | 1.33 (1.10–1.64) | < 0.001 |
| LDL-C (mmol/l) | 2.73 (2.26–3.26) | 2.52 (2.04–3.05) | < 0.001 |
| Apo-A1 (g/l) | 1.26 (1.11–1.45) | 1.35 (1.16–1.53) | < 0.001 |
| Apo-B (g/l) | 0.95 (0.80–1.14) | 0.86 (0.72–1.03) | < 0.001 |
| eGFR (ml/(min·1.73 m2)) | 108.1 (96.5–121.9) | 110.8 (98.4–125.8) | < 0.001 |
Fig. 1The association between baseline TyG index and the cumulative incidence of NAFLD
Fig. 2The univariate Cox hazard models of development of NAFLD during 9-year follow-up
Fig. 3The multivariate Cox hazard models of development of NAFLD during 9-year follow-up
Fig. 4Risk of development NAFLD according to baseline TyG quartiles in unadjusted and adjusted models. Model 1: Adjusted for age and gender; Model 2: Adjusted for indictors of MS including age, gender, WC, SBP, DBP, FPG, HDL-C and TG; Model 3: Adjusted for age, gender, WC, BMI, SBP, DBP, TC, TG, HDL-C, LDL-C, Apo-A1, Apo-B, FPG, BUN, Cr, AST, ALT, y-GGT, UA and eGFR
Fig. 5Receiver operative characteristic (ROC) curves and corresponding areas under the curve (AUC) for NAFLD. The AUC of TG, ALT, FPG and TyG were 0.70 (95% CI 0.69–0.72), 0.70 (95% CI 0.69–0.72), 0.57 (95% CI 0.55–0.59) and 0.76 (95% CI 0.74–0.77), respectively. p values for the difference between TyG and other two AUCs were < 0.0001